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Abstract
Background—The diagnosis of genetic
haemochromatosis (GH) before iron over-
load has developed is diYcult. However a
convincing candidate gene for GH, HFE
(previously HLA-H), has been described
recently.
Aims—To determine the prevalence of the
haemochromatosis associated HFEmuta-
tions C282Y and H63D in United Kingdom
aVected and control populations.
Methods—The prevalence of the HFE
C282Y and H63D mutations was deter-
mined by polymerase chain reaction am-
plification and restriction enzyme
digestion in a cohort of 115 well character-
ised patients with GH and 101 controls
from the United Kingdom.
Results—One hundred and five of 115
(91%) patients with GH were homozygous
for the C282Y mutation. Only one of 101
(1%) controls was homozygous for the
C282Y mutation and this individual cur-
rently shows evidence of iron overload.
Two of five patients who did not have
either of the two described mutations of
HFE had early onset iron overload (ages
16 and 24). One had a family history of
cardiac failure and the second was subse-
quently hospitalised due to cardiac fail-
ure. These are the first phenotypic
observations for patients without either
C282Y or H63D mutation of HFE.
Conclusion—This simple genetic test
promises to be a highly eVective tool in the
diagnosis of GH.
(Gut 1997; 41: 841–844)
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Genetic haemochromatosis is an autosomal
recessive disorder resulting in iron overload. In
northern European populations, where the dis-
ease is believed to have originated, as many as
1 in 300 individuals are aVected.1 2 Unrecog-
nised, the iron loading results in tissue damage
aVecting the liver, pancreas, joints, anterior
pituitary, and heart.3 Early diagnosis and treat-
ment by repeated venesection is eVective and
restores normal life expectancy.4 However,
detection of sporadic genetic haemochromato-
sis in the early, asymptomatic phase may be
diYcult in the absence of a reliable test.
Simon et al showed that the gene responsible
for genetic haemochromatosis mapped close to
the major histocompatibility complex (MHC)
locus HLA-A (6p21.3).5 About 50% of genetic
haemochromatosis chromosomes carry an ex-
tended “ancestral” haplotype of chromosome 6
microsatellite marker alleles (D6S265-1,
D6S105-8, D6S1260-4 which includes HLA-
A3), reflecting the haplotype of the founder
mutation.6 In the absence of information about
the biochemical defect in genetic haemochro-
matosis, positional cloning has been used in the
search for the gene. Recently, we showed that
the gene mapped telomeric to HLA-A, close to
the microsatellite marker D6S1260.6 Extension
of this approach led to the identification of a
strong candidate gene for genetic haemochro-
matosis, termed HFE7 (previously HLA-H).
The direct evidence on which this claim was
based centred on the high frequency (83%) of
US patients with genetic haemochromatosis
homozygous for a single mutation (C282Y),
the association of this mutation with the ances-
tral haplotype, and the proposed functional
consequences of this mutation. We have
studied the prevalence of mutations in this
gene in a cohort of UK patients with genetic
haemochromatosis identified by strict diagnos-
tic criteria.
Patients and Methods
DNA was prepared from blood samples
obtained from patients with haemochromatosis
diagnosed and managed at four UK centres
(King’s College Hospital, Royal Free Hospital,
John RadcliVe Hospital, and the University
Hospital of Wales). The diagnosis of genetic
haemochromatosis was confirmed on the basis
of a hepatic iron index of greater than 1.9, or
greater than 5 g mobilisable iron by quantita-
tive phlebotomy, in the absence of any other
cause of iron loading. Thirty five per cent of the
115 patients with genetic haemochromatosis
studied had at least one other known aVected
family member. Control samples were ob-
tained from a series of 101 healthy blood
donors from South Wales.8
HFE gene analysis was performed by
polymerase chain reaction (PCR) amplification
of total genomic DNA of the two regions of the
HFE gene carrying the mutations C282Y and
H63D.7 The G to A transition (aa282) creates
a new RsaI site; there is a second RsaI site in
this fragment which acts as an internal control
in the restriction fragment length polymor-
phism (RFLP) analysis. The C to G transver-
sion (aa63) results in the loss of BclI and MboI
sites in the amplified product allowing typing
by RFLP. Results were confirmed by relocating
the 3' primer (5' CTT GCT GTG GTT GTG
ATTTTCC 3') to include a secondMboI site,
thus providing an internal control.
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Results
One hundred and fifteen unrelated patients
with genetic haemochromatosis and 101 con-
trols were genotyped (table 1). The frequency
of the C282Y mutation was 93% and 6% in
patient and control chromosomes respectively.
Homozygosity for this mutation was seen in
91% of patients and only 1% of controls.
Homozygosity for the C282Y mutation was
seen in 38/40 patients with genetic haemochro-
matosis with a positive family history, which
was not significantly diVerent from 67/75
patients with genetic haemochromatosis with-
out a family history (÷2=0.046, p=0.50). Of the
99 patients for which we had full haplotype
information, 23 were homozygous for the
extended ancestral haplotype (D6S265-1,
D6S105-8, D6S1260-4 which includes HLA-
A3) and homozygous for the C282Y mutation.
The H63D variant was present in 2% of
haemochromatosis and 16% of control chro-
mosomes. One patient and three controls
were homozygous for this variant. There was
no evidence of iron loading in these three
controls.
None of the patients homozygous for the
C282Y mutation carried the H63D variant.
However, three patients and four controls were
heterozygous for both the C282Y and H63D
mutations (compound heterozygotes). These
three compound heterozygote patients had
mild disease as evidenced by initial quantitative
phlebotomy removing circa 5 g iron. The four
controls who were compound heterozygotes
showed no signs of iron loading.
Four of the six haemochromatotic patients
without the C282Y mutation had clinical and
biochemical features typical of genetic haemo-
chromatosis (table 2). The remaining two
however had early onset of iron overload.
Patient 1 was diagnosed with heart failure at 29
years of age. On reviewing his history, he had
displayed features of hypogonadotropic hy-
pogonadism five years earlier (age 24). The
diagnosis of genetic haemochromatosis was
made on the basis of serum iron studies (serum
iron 31 µmol/l, total iron binding capacity
(TIBC) 33 µmol/l, ferritin 3350 µg/l), myocar-
dial biopsy, and the quantitation of iron
overload. Initial desferrioxamine treatment for
52 days removed 3.5 g iron. Venesection
therapy, commenced in parallel with the iron
chelation, was continued over 13.5 months
removing an additional 11 g iron. In total,
14.5 g iron was removed in 13.5 months.
Patient 1 has had no transfusions, and has no
known family history, as he is adopted. His
genotype (D6S265 1,3;D6S105 6,8;D6S1260
3,4; D6S1621 5,6) does not provide suYcient
information to exclude the possible presence of
one copy of the ancestral haplotype, but reveals
that he is not homozygous for the ancestral
haplotype.
Patient 2 was diagnosed at the age of 16 dur-
ing family screening. His elder brother had
presented at age 21 with gross heart failure and
on investigation was found to have micronodu-
lar cirrhosis and massive iron overload on liver
biopsy. The brother had died of an asystolic
cardiac arrest while in hospital before treat-
ment could be started. On biochemical screen-
ing patient 2 was found to have a serum iron
concentration of 42 µmol/l, TIBC of 44 µmol/l,
ferritin of 2082 µg/l, and on liver biopsy grade
4 siderosis but minimal fibrosis. He has no
abnormality of copper metabolism as deter-
mined by biochemical analysis. He became
iron deficient after the removal of 10 g iron by
venesection and during the follow up period of
20 years required regular venesection to main-
tain normal iron indexes. Microsatellite analy-
sis for patient 2 revealed a haplotype (D6S265
3,6; D6S105 6,8; D6S1260 4,4; D6S1621
7,10) in which neither chromosome demon-
strates the founder haplotype.
Discussion
We confirm the remarkably strong association
between the C282Y mutation in HFE and
genetic haemochromatosis as recently re-
ported.7 The observed homozygosity for this
mutation was higher in this sample of UK
haemochromatosis patients than that reported
in the original sample from the USA (91% ver-
sus 83%, ÷2=3.95, p=0.047). Recent reports
have confirmed the high frequency of homozy-
gosity for the C282Y mutation in patients with
genetic haemochromatosis, and reveal consist-
ent results in similar populations. Thus, two
American studies have now reported 83% and
82% homozygosity for C282Y7 9; 92% ho-
mozygosity was observed in a French Breton
series,10 similar to this UK study (91%
homozygosity) and 100% occurred in an Aus-
TABLE 1 Genotype frequencies for mutations in HLA-H
Genotypes
TotalHH/YY HH/CC HD/CC HD/CY HH/CY DD/CC
GH 105 5 0 3 1 1 115
Controls 1 65 22 4 6 3 101
Genotypes are given for amino acid 63/amino acid 282 of the polypeptide (C, cysteine; D, aspar-
tic acid; H, histidine; Y, tyrosine). HH/CC = normal (wild type) and HH/YY = homozygosity for
the C282Y mutation. GH, genetic haemochromatosis.
TABLE 2 Clinical details of patients not carrying the C282Y mutation
Patient Genotype
Known family
history
Age at onset of
symptoms (y)
Iron removed by initial
venesection/desferrioxamine (g)
Liver histology/grade of
siderosis
Serum
Fe/TIBC
(µmol/l)
Transferrin
saturation (%)
Serum ferritin
(µg/l)
1 HH/CC No (adopted) 24 14 – 31/33 94 3350
2 HH/CC Yes 16* 10 Fibrosis/4 42/44 95 2082
3 HH/CC No 60 7 Fibosis/2 (HII-5.6) 37.6/44.9 84 1350
4 HH/CC No 55 NA† Cirrhosis NA 80 595
5 HH/CC No 54 5 Fibrosis/3 40/54 74 1400
6 DD/CC No 36 > 10 Cirrhosis/heavy
siderosis
60/65 92 7000
* Diagnosed at age 16 during family screening.
† Died shortly after diagnosis.
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tralian study,11 possibly reflecting recent migra-
tion and a secondary founder eVect.
The frequency of the C282Y mutation in
control chromosomes observed by us is com-
patible with the predicted carrier rate for the
haemochromatosis allele of approximately
10%.12 In the present study we found one con-
trol who was homozygous for the C282Y
mutation. This subject was found to have a
transferrin saturation of 70% and is currently
being investigated. These data together sup-
port the proposal that the C282Y mutation in
HFE represents the ancestral genetic haemo-
chromatosis mutation. Final confirmation re-
quires functional analyses.
The significance of compound heterozygos-
ity (heterozygosity for both the C282Y and
H63D mutations) is not clear as we found
similar numbers in patients and controls.
Three haemochromatosis patients and four
controls were compound heterozygotes. Two
additional patients with suspected genetic
haemochromatosis failed to meet diagnostic
criteria for entry into the study but were subse-
quently investigated and found to be com-
pound heterozygotes.
Five patients lacked either mutation. Three
of these presented classically in middle age.
However, the remaining two patients presented
early (ages 16 and 24 years). One patient
developed haemochromatotic cardiomyopathy
and the second had a family history of cardiac
disease. Neither of these two patients were
homozygous for the ancestral haplotype. Possi-
ble causes for heterogeneity of genetic haemo-
chromatosis include: other mutations of HFE;
mutations in other causative genes; functional
polymorphism of genes which modify the phe-
notype; environmental eVects; and combina-
tions of the above.
The screening method we and others10 have
used involves RFLP analysis of PCR products
with RsaI. This method is rapid and straight-
forward, and can be subjected to quality
control as the PCR product has a built in con-
trol RsaI site. This method can therefore be
easily transferred to any regional genetics or
routine hospital laboratory as it does not
require sophisticated automated technology.
The high sensitivity and specificity of this
genetic test make it ideally suited for the
preliminary investigation of family members of
aVected patients and for screening individuals
with liver disease or biochemical evidence of
iron overload.
Although the majority of patients with
genetic haemochromatosis are homozygous for
C282Y, it remains to be established whether all
homozygous individuals would develop iron
overload. Data from a group of patients with
porphyria cutanea tarda (PCT) provide the
first evidence on this question of development
of iron overload. PCT is another iron depend-
ent condition in which iron removal by
phlebotomy produces prolonged biochemical
and clinical remission. However, patients with
PCT rarely accumulate as much iron as do
patients with genetic haemochromatosis. Rob-
erts et al have recently shown that over 40% of
patients with sporadic PCT have at least one
copy of the C282Y mutation.13 Seven of the 41
patients were homozygous for this mutation.
These patients presented at a mean age of 67
years, but none had developed clinically
significant iron overload. This shows that an
undetermined proportion of C282Y homozy-
gotes may live for 60 years or more without
developing iron overload leading to tissue
damage. To determine this proportion will
require large scale screening for this mutation
along with measures of iron status. This
group of patients may prove helpful in
elucidating the biology of genetic haemochro-
matosis.
Genetic haemochromatosis should no longer
be considered a rare condition1 2 and this has
important health implications. In this study,
one C282Y homozygote was identified out of
101 controls, and this individual showed
evidence of iron loading. In another study, two
out of 368 random UK samples were found to
be homozygous for C282Y.14
Prior to the identification of the candidate
gene, universal biochemical screening was pro-
posed based on cost benefit analysis.15 The
Center for Disease Control has recommended
that the entire US population be screened for
haemochromatosis by transferrin saturation.16
Genetic analysis will provide a rapid and
specific way of identifying those at risk from
iron overload in the general population.
Genotyping individuals for the C282Y
mutation makes it possible to identify those at
risk in the early asymptomatic phase of the dis-
ease. Individuals who are homozygous for this
mutation should be considered at risk for
developing iron overload. Whether or not all
such subjects develop major iron overload
remains to be determined. Before this genetic
test is adopted, ethical issues need to be
addressed, such as how insurance companies
will view homozygous C282Y individuals
without iron overload or tissue damage.
Powell17 has stated that if normal iron concen-
trations are maintained by regular phlebotomy,
these patients should not be denied life
insurance or have their premiums raised. How-
ever, the advantage of this genetic test will lie in
early detection. It is widely accepted that
venesection carried out before the onset of tis-
sue damage will restore normal life
expectancy.4
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